StellarCube takes part in K-BIO NJ Summit 2025, stepping onto the global stage
A new bridgehead for Korea–US bio cooperation
StellarCube, an AI and data-driven biotech company, announced that it had taken part officially in K-BIO NJ Summit 2025, held in New Jersey, presenting AI–bio converged technology aimed at transforming the fields of aging, wellness and pain management.
K-BIO NJ Summit 2025 was jointly organized by Choose New Jersey, the Korea Culture and Economic Development Institute (KCED) and the Korean chapter of the Hudson County Chamber of Commerce, and is regarded as a global public–private cooperation platform connecting the bio industries of Korea and the United States.
The summit was hosted jointly by Choose New Jersey, which represents economic development in New Jersey; KCED, which has connected Korean industry and business communities with the US market; and the Korean chapter of the Hudson County Chamber of Commerce, which links New Jersey's local community, government and industry.
Biotech and healthcare companies, academia and research institutions took part, making the event an opportunity to further strengthen investment, technology cooperation and industrial links between the two countries.
At the summit, StellarCube presented the direction of next-generation medical technology and its vision for global expansion, centered on AI bioinformatics, predictive analytics platforms and digital health ecosystem strategy.
StellarCube CEO Jinseob Noh and the R&D team have built a proprietary AI-based bioinformatics platform spanning healthcare, gaming and smart medical devices, and drew particular attention for medical AI technology capable of measuring, predicting and personalizing pain, aging and chronic disease through integrated analysis of biosignals, clinical data and user data.
Noh said: "This summit was an opportunity to move forward with the global health data strategy StellarCube has been pursuing and with cooperation in the US market. By combining AI and life sciences, we will offer new solutions in aging and pain management."
He added: "Through cooperation with the New Jersey bio ecosystem, we will further strengthen our competitiveness in the global healthcare market."